Le Guevelou J, Cuccia F, Flippot R, Ferrera G, Terlizzi M, Zilli T et al. The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. [Online ahead of print]

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol. 2020;6:650–9.

Article  PubMed Central  PubMed  Google Scholar 

Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36:446–53.

Article  CAS  PubMed  Google Scholar 

Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9:825–34.

Article  PubMed Central  PubMed  Google Scholar 

Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023;41:5561–8.

Article  CAS  PubMed  Google Scholar 

Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial. J Clin Oncol. 2024;42:38–46.

Article  CAS  PubMed  Google Scholar 

Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.

Article  CAS  PubMed  Google Scholar 

Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.

Article  PubMed  Google Scholar 

Jadvar H, Abreu AL, Ballas LK, Quinn DI. Oligometastatic Prostate Cancer: Current Status and Future Challenges. J Nucl Med. 2022;63:1628–35.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, et al. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022;40:3377–82.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–e28.

Article  PubMed  Google Scholar 

Sonpavde G. The biology of prostate cancer metastases: does oligo differ from polymetastatic? Curr Opin Urol. 2017;27:542–6.

Article  PubMed  Google Scholar 

Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14:15–25.

Article  CAS  PubMed  Google Scholar 

Bauckneht M, Lanfranchi F, Albano D, Triggiani L, Linguanti F, Urso L, et al. Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study). J Nucl Med. 2024;65:1202–9.

Article  PubMed Central  PubMed  Google Scholar 

Nikitas J, Castellanos Rieger A, Farolfi A, Seyedroudbari A, Kishan AU, Nickols NG, et al. Prostate-Specific Membrane Antigen PET/CT-Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024;65:1387–94.

Article  PubMed  Google Scholar 

Sabbagh A, Mohamad O, Lichter KE, Hope TA. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. Cancers. 2022;14:6194.

Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199–207.

Article  PubMed  Google Scholar 

Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. J Nucl Med. 2022;63:59–68.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Gauthé M, Sargos P, Barret E, Fromont-Hankard G, Beauval JB, Brureau L et al. Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review. J Clin Med. 2021;10:4909.

Grkovski M, O’Donoghue JA, Imber BS, Andl G, Tu C, Lafontaine D, et al. Lesion Dosimetry for [(177)Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate Cancer. J Nucl Med. 2023;64:1779–87.

Article  PubMed Central  CAS  PubMed  Google Scholar 

Suman SK, Subramanian S, Mukherjee A. Combination radionuclide therapy: A new paradigm. Nucl Med Biol. 2021;98-99:40–58.

Article  CAS  PubMed  Google Scholar 

Chen R, Wang Y, Zhu Y, Shi Y, Xu L, Huang G, et al. The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer. J Nucl Med. 2022;63:69–75.

Article  PubMed Central  PubMed  Google Scholar 

Qu XM, Chen Y, Zaric GS, Senan S, Olson RA, Harrow S, et al. Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial. Int J Radiat Oncol Biol Phys. 2021;109:1176–84.

Article  PubMed  Google Scholar